RLMD relmada.com: Quarterly EPS earnings growth

Brandmark of Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics (RLMD) minimizes operational risks through the diversification of external manufacturing laboratories. Historical quarterly EPS growth demonstrates margin dynamics, where the 59.50 metric determines this level. The valuation foundation is based on the safety of the REL-1017 drug for depression therapy, while demand for neuromedicine remains consistently high regardless of economic cycles and GDP fluctuations.

Relmada Therapeutics Inc (RLMD) - Quarterly EPS earnings growth from 07/04/2022 to 11/14/2026

Relmada Corp - analytical breakdowns and key metrics (RLMD)

- share price and expert price forecast:
Stock Price Relmada Therapeutics, Inc.|RLMD - Analyst Consensus Forecast
- company stock capitalization data:
Market Capitalization Relmada|RLMD - Business Value
- balance sheet net asset value indicators:
Book Value per Share Relmada Therapeutics|RLMD - Book Capitalization|Market Cap to Net Assets Ratio relmada.com|RLMD - Aggregate Asset Value
- debt and solvency information:
Total Debt to Equity Ratio Relmada Therapeutics|RLMD - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Relmada Therapeutics|RLMD - Aggregate Debt Obligations|Debts to Book Capitalization Relmada|RLMD - Long-Term Debt|Company Short-Term Debt Relmada Therapeutics|Quick Ratio relmada.com
- earnings and valuation multiples indicators:
RLMD - Net Profit|Expected Profit Relmada Therapeutics|RLMD - Market Cap to Net Income|Forward P/E Multiple Relmada|RLMD - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Relmada|RLMD - Operating profit EBITDA|Net earnings per share for the last 12 months Relmada Therapeutics|RLMD - Earnings per share for the last four quarters|Quarterly EPS earnings growth relmada.com|RLMD - Expected net earnings per share growth this year|Earnings growth forecast for next year Relmada Therapeutics
- revenue and sales details:
RLMD - Company Sales|Company Projected Revenue Relmada Therapeutics, Inc.|RLMD - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Relmada
Summary company analytics:Relmada Therapeutics, Inc. - RLMD
Finished products of Relmada Corp

The scientific potential of the drug REL-1017 in depression therapy drives the long-term value of Relmada Therapeutics (RLMD), which investors must weigh against profit dynamics. By analyzing the current quarterly EPS growth rate, calculated as the percentage change in net income per share compared to the same period last year, one can assess the efficiency of intellectual asset capitalization and the overall investment stability of the issuer.

Analysis of competing companies

BIIB: Quarterly EPS earnings growth|Neurocrine (NBIX) - Quarterly EPS earnings growth|RGC (Regencell) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months AXSM (Axsome Corp)|Quarterly EPS earnings growth ACAD|Quarterly EPS earnings growth xenon-pharma.com (XENE)|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months SUPN|CPRX: Year-over-year net earnings per share growth for the last 12 months|Denali Corp - Year-over-year earnings per share growth rate for the last twelve months|HRMY: Quarterly EPS earnings growth|biohavenpharma.com - Year-over-year earnings per one share growth for the last 12 months|AMLX (Amylyx Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Trevi Therapeutics Inc TRVI|Year-over-year earnings per share growth for the last twelve months Praxis Medicines (PRAX)|AVXL (Anavex Life Sciences Corp) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CBLL (CeriBell, Inc.)|Quarterly EPS earnings growth prothena.com PRTA|ALEC - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months ANNX|OMER: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurogene Therapeutics (NGNE)|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth voyagertherapeutics.com|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|Year-over-year earnings per share growth rate for the last twelve months SCLX|Quarterly EPS earnings growth TVGN (Tevogen Bio Holdings, Inc.)|Year-over-year net earnings per share change for the last twelve months Alpha Cognition Inc (ACOG)|Cognition Therapeutics, Inc. - Quarterly EPS earnings growth|inhibikase.com (IKT) - Year-over-year net earnings per share growth for the last 12 months|Cassava Sciences (SAVA) - Year-over-year earnings per share growth for the last twelve months|ASRT - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Coya Therapeutics Inc|VTGN: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Ovid Therapeutics Inc. (OVID)|Year-over-year earnings per share growth for the last twelve months ABOS (acumenpharm.com)|Year-over-year earnings per share growth for the last twelve months CervoMed CRVO|ATHE - Year-over-year net earnings per share growth for the last 12 months|Clene Nanomedicine - Quarterly EPS earnings growth|PEPG (PepGen Inc.) - Year-over-year earnings per share growth for the last 12 months|Jupiter Neurosciences (JUNS) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months ANVS|GRCE (Grace Therapeutics Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Firefly Neuroscience, Inc. AIFF|Year-over-year net earnings per share growth for the last 12 months KLTO (Klotho Neurosciences Inc)|Quarterly EPS earnings growth neurosense-tx.com (NRSN)|Year-over-year earnings per share growth for the last twelve months Reviva Pharmaceuticals RVPH|Year-over-year earnings per one share growth for the last 12 months MTVA|NRXS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Helius Medical|passagebio.com (PASG) - Year-over-year earnings per share growth for the last twelve months|Neuphoria Therapeutics - Year-over-year earnings per one share growth for the last 12 months|NERV (Minerva Neurosciences) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months athira.com ATHA|Year-over-year earnings per share growth for the last twelve months Addex Therapeutics Ltd (ADXN)|Year-over-year earnings per share growth for the last twelve months ALZN (alzamend.com)|Year-over-year earnings per share growth for the last twelve months Cyclerion Therapeutics, Inc. CYCN|PTIX - Year-over-year net earnings per share growth for the last 12 months|Pasithea - Quarterly EPS earnings growth|CRGT - Quarterly EPS earnings growth|ATXI: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months BCLI|CARA (Cara Therapeutics, Inc) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Chromocell|Year-over-year net earnings per share growth for the last 12 months ELYM (Eliem Therapeutics)|ITCI (intracellulartherapies.com) - Year-over-year earnings per one share growth for the last 12 months|Longboard Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months MRNS (Marinus Pharmaceuticals Inc)|NKGen - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months NRBO (NeuroBo Pharma)|SAGE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months synaptogen.com (SNPX)|Year-over-year earnings per share growth for the last twelve months Trevena|VIGL: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth Cerevel Corp (CERE)